ArticleRadiology case reports2026
Superselective intra-arterial infusion of cisplatin and concomitant radiation therapy (RADPLAT) using gadolinium-based contrast agent in a patient with severe iodine allergy: A case report.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maxillary sinus squamous cell carcinoma (MS-SCC) is a rare malignancy that is often diagnosed at an advanced stage. We report a case of locally advanced MS-SCC that was successfully treated with super-selective intra-arterial cisplatin infusion concurrent with radiotherapy (RADPLAT) using gadolinium-based contrast agents due to a severe allergy to iodinated contrast media. Despite limitations in image quality, gadolinium-based contrast agents enable sufficient visualization with digital subtraction angiography and computed tomography angiography. Seven treatment sessions were completed without adverse events, using a maximum gadolinium dose of 28 mL per session. Post-treatment imaging revealed no residual tumors. This case illustrates the feasibility of using gadolinium-based contrast agents as an alternative to iodinated contrast media for angiographic guidance during RADPLAT in patients with contraindications to iodinated contrast. However, its long-term safety warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.